A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo

[1]  A. Giordano,et al.  Identification of murine cdk10: Association with Ets2 transcription factor and effects on the cell cycle , 2006, Journal of cellular biochemistry.

[2]  P. Claudio,et al.  Cell cycle control and beyond: emerging roles for the retinoblastoma gene family , 2006, Oncogene.

[3]  W. Du,et al.  Retinoblastoma family genes , 2006, Oncogene.

[4]  A. Giordano,et al.  Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes , 2006, Oncogene.

[5]  A. Giordano,et al.  Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf‐1, p27, and PCNA in Barrett's esophagus , 2006, Journal of cellular physiology.

[6]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Giordano,et al.  Interaction of PP2A catalytic subunit with Rb2/p130 is required for all‐trans retinoic acid suppression of ovarian carcinoma cell growth , 2006, Journal of cellular physiology.

[8]  A. Giordano,et al.  Role of cell‐cycle regulators in lung cancer , 2005, Journal of cellular physiology.

[9]  M. Barbacid,et al.  Mammalian cyclin-dependent kinases. , 2005, Trends in biochemical sciences.

[10]  A. Giordano,et al.  Are RB proteins a potential substrate of Pin1 in the regulation of the cell cycle? , 2005, Journal of cellular physiology.

[11]  A. Giordano,et al.  Tumor-specific exon 1 mutations could be the ‘hit event’ predisposing Rb2/p130 gene to epigenetic silencing in lung cancer , 2005, Oncogene.

[12]  Dario La Sala,et al.  Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: implications for pathogenesis and therapeutic approach , 2005, Oncogene.

[13]  P. Åman,et al.  Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. , 2004, International journal of oncology.

[14]  J. Maller,et al.  A Centrosomal Localization Signal in Cyclin E Required for Cdk2-Independent S Phase Entry , 2004, Science.

[15]  M. Tsao,et al.  Overexpression of G1-S Cyclins and Cyclin-Dependent Kinases during Multistage Human Pancreatic Duct Cell Carcinogenesis , 2004, Clinical Cancer Research.

[16]  P. Fischer,et al.  Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. , 2004, Organic & biomolecular chemistry.

[17]  Chun-ching Lin,et al.  Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. , 2004, Life sciences.

[18]  Y. Bang,et al.  Cdk2-dependent phosphorylation of the NF-Y transcription factor is essential for the expression of the cell cycle-regulatory genes and cell cycle G1/S and G2/M transitions , 2004, Oncogene.

[19]  Yu-Chih Liang,et al.  Anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one (BJ-601) on human vascular endothelial cells: G0/G1 p21-associated cell cycle arrest. , 2004, Biochemical pharmacology.

[20]  Jian Wang,et al.  Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. , 2004, Biochemical and biophysical research communications.

[21]  S. Grant,et al.  Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents , 2004, Current oncology reports.

[22]  K. Keyomarsi,et al.  Activation of Cyclin-dependent Kinase 2 by Full Length and Low Molecular Weight Forms of Cyclin E in Breast Cancer Cells* , 2004, Journal of Biological Chemistry.

[23]  W. A. Yeudall,et al.  Accelerated Cell Cycle Progression in Osteoblasts Overexpressing the c-fos Proto-oncogene , 2004, Journal of Biological Chemistry.

[24]  Xiangyuan Wang,et al.  Elevated levels and distinct patterns of expression of A‐type cyclins and their associated cyclin‐dependent kinases in male germ cell tumors , 2004, International journal of cancer.

[25]  P. Kaldis,et al.  Cdk2 Knockout Mice Are Viable , 2003, Current Biology.

[26]  A. Senderowicz.  Small-molecule cyclin-dependent kinase modulators , 2003, Oncogene.

[27]  Yan Geng,et al.  Cyclin E Ablation in the Mouse , 2003, Cell.

[28]  Pierre Dubus,et al.  Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice , 2003, Nature Genetics.

[29]  P. Fischer,et al.  CDK inhibitors in clinical development for the treatment of cancer , 2003, Expert opinion on investigational drugs.

[30]  Frank McCormick,et al.  Proliferation of cancer cells despite CDK2 inhibition. , 2003, Cancer cell.

[31]  C. Fegan,et al.  Flavopiridol circumvents Bcl‐2 family mediated inhibition of apoptosis and drug resistance in B‐cell chronic lymphocytic leukaemia , 2001, British journal of haematology.

[32]  F. Sarkar,et al.  Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. , 2000, International journal of oncology.

[33]  E. Sausville,et al.  Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication* , 2000, The Journal of Biological Chemistry.

[34]  P. Stiegler,et al.  Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop. , 2000, Cancer research.

[35]  J. Minna,et al.  Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. , 2000, Cancer research.

[36]  A. Senderowicz,et al.  Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. , 1999, International journal of oncology.

[37]  E. Nishida,et al.  Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells , 1999, Current Biology.

[38]  L. Meijer,et al.  The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. , 1998, Experimental cell research.

[39]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[40]  A. Giordano,et al.  A Unique Domain of pRb2/p130 Acts as an Inhibitor of Cdk2 Kinase Activity* , 1997, The Journal of Biological Chemistry.

[41]  B. Dynlacht,et al.  p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity , 1997, Molecular and cellular biology.

[42]  Priscille Brodin,et al.  A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus* , 1997, The Journal of Biological Chemistry.

[43]  Y. Xiong.  Why are there so many CDK inhibitors? , 1996, Biochimica et biophysica acta.

[44]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[45]  A. Giordano,et al.  Functional analysis of pRb2/p130 interaction with cyclins. , 1996, Cancer research.

[46]  B. Dynlacht,et al.  p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. , 1995, Genes & development.

[47]  S. Reed,et al.  Different roles for cyclins D1 and E in regulation of the G1-to-S transition , 1995, Molecular and cellular biology.

[48]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[49]  James M. Roberts,et al.  Human cyclin E, a nuclear protein essential for the G1-to-S phase transition , 1995, Molecular and cellular biology.

[50]  E. Harlow,et al.  The pRB‐related protein p107 contains two growth suppression domains: independent interactions with E2F and cyclin/cdk complexes. , 1995, The EMBO journal.

[51]  G. Condorelli,et al.  p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. , 1994, Cancer research.

[52]  J. Gibbs,et al.  Pharmaceutical research in molecular oncology , 1994, Cell.

[53]  E. Sausville,et al.  Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.

[54]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[55]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[56]  A. Giordano,et al.  Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. , 1993, Oncogene.

[57]  D O Morgan,et al.  Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. , 1992, The EMBO journal.

[58]  James M. Roberts,et al.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle , 1992 .

[59]  C. Anderson,et al.  The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. , 1991, The EMBO journal.

[60]  B. Franza,et al.  Cell cycle regulation of histone H1 kinase activity associated with the adenoviral protein E1A. , 1991, Science.

[61]  B. Franza,et al.  A 60 kd cdc2-associated polypeptide complexes with the E1A proteins in adenovirus-infected cells , 1989, Cell.

[62]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[63]  A. Giordano,et al.  Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. , 1995, Critical reviews in eukaryotic gene expression.

[64]  L. Bonetta,et al.  CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. , 1994, Oncogene.